Evidence map›Paper›PMID 31870124›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2019

Natural Killer Cell Expansion with Autologous Feeder Layer and Anti-CD3 Antibody for Immune Cell Therapy of Hepatocellular Carcinoma.

Faezeh Hosseinzadeh, Jafar Ai, Somayeh Ebrahimi-Barough, Iman Seyhoun, Abbas Hajifathali, Samad Muhammadnejad, Fatemeh Hosseinzadeh, Mahdi Shadnoush, Farnaz Dabiri Oskouei, Javad Verdi

Open access · goldAbstract read
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Faezeh HosseinzadehDepartment of Tissue Engineering and Applied Cell Sciences,School of Advanced Technologies in Medicine,Tehran University of Medical Sciences, Tehran, Iran.
Jafar AiDepartment of Tissue Engineering and Applied Cell Sciences,School of Advanced Technologies in Medicine,Tehran University of Medical Sciences, Tehran, Iran.
Somayeh Ebrahimi-BaroughDepartment of Tissue Engineering and Applied Cell Sciences,School of Advanced Technologies in Medicine,Tehran University of Medical Sciences, Tehran, Iran.
Iman SeyhounDepartment of Tissue Engineering and Applied Cell Sciences,School of Advanced Technologies in Medicine,Tehran University of Medical Sciences, Tehran, Iran.ORCID 0000-0002-8216-7933
Abbas HajifathaliTaleghani Bone Marrow Transplantation Center,Taleghani Hospital,Shahid Beheshti University of Medical Sciences,Tehran, Iran.
Samad MuhammadnejadCell-Based Therapies Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Fatemeh HosseinzadehDentistry Faculty, Tehran University of Medical Sciences, Tehran, Iran.
Mahdi ShadnoushDepartment of Clinical Nutrition, Faculty of Nutrition & Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Farnaz Dabiri OskoueiDepartment of Stem Cell Therapy, Tabriz Valiasr Hospital, Tabriz, Iran.
Javad VerdiDepartment of Tissue Engineering and Applied Cell Sciences,School of Advanced Technologies in Medicine,Tehran University of Medical Sciences, Tehran, Iran.
Tehran University of Medical Sciences · IRNational Nutrition and Food Technology Research Institute · IRQom University of Medical Science and Health Services · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundone of the promising approaches for treatment of some cancers is adoptive cell therapy using natural killer (NK) cells. Various methods have been investigated for ex vivo expansion of NK cells in large-scale, but most of them involved cancer or genetically modified cells as feeder layer and also some of them have the risk of T cell contamination and graft-versus-host disease (GVHD).

methodIn this study, irradiated autologous peripheral blood mononuclear cells (PBMCs) as feeder layer with an anti-CD3 monoclonal antibody (mAb) were used. For activation and expansion of NK cells, human recombinant IL2 and IL15 were used. After co-culturing of expanded NK cells (eNKC) and isolated NK cells (iNKC) with hepatocellular carcinoma (HCC) cells, the viability of eNKC in compared to iNKC were analyzed by CCK-8 assay and degranulation of NK cells after co-culturing was assayed by measuring CD107a expression. Enzyme-Linked Immunosorbent Assay (ELISA) assay was used for the ability of NK cells to secretion of IFN-γ (interferon-γ) and TNF-α (Tumor Necrosis Factor-α) after co-culture with HCC cells. Real Time PCR analysis was used for expression of human Perforin and Granzyme B genes in the NK cells exposed to target HepG2 cells.

resultThis method strongly expanded highly purified NK cells with powerful cytotoxicity against HCC cells. The expanded NK cells showed high level of expression of degranulation marker and human Perforin and Granzyme B genes, and also was secreted larger amounts of TNF-α and IFN-γ compared with fresh isolated NK cells.

conclusionwe proposed an effective method for expansion of cytotoxic NK cells using irradiated autologous PBMC as feeder layer for more successful transfer of allogeneic NK cell in immuno cell therapy of HCC.

Indexed as

Cell- and Tissue-Based TherapyAntibodies, MonoclonalCarcinoma, HepatocellularCD3 ComplexCell ProliferationCytotoxicity, ImmunologicFeeder CellsHep G2 CellsHumansImmunotherapyKiller Cells, NaturalLeukocytes, MononuclearLiver NeoplasmsLymphocyte ActivationAntibodies, MonoclonalCD3 ComplexHepatocellular carcinomaimmune cell therapyNatural Killer cell expansion

Identifiers

PMID31870124
PMCPMC7173374
OpenAlexW2997606928

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.